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A B S T R A C T
Purpose
The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression
remains inconclusive. We investigated the prevalence and distribution of mutations in these genes
in different melanoma tissues.
Patients and Methods
In all, 291 tumor tissues from 132 patients with melanoma were screened. Paired samples of
primary melanomas (n  102) and synchronous or asynchronous metastases from the same
patients (n  165) were included. Tissue samples underwent mutation analysis (automated DNA
sequencing). Secondary lesions included lymph nodes (n 84), and skin (n 36), visceral (n 25),
and brain (n  44) sites.
Results
BRAF/NRAS mutations were identified in 58% of primary melanomas (43% BRAF; 15% NRAS);
62% in lymph nodes, 61% subcutaneous, 56% visceral, and 70% in brain sites. Mutations
were observed in 63% of metastases (48% BRAF; 15% NRAS), a nonsignificant increase in
mutation frequency after progression from primary melanoma. Of the paired samples, lymph
nodes (93% consistency) and visceral metastases (96% consistency) presented a highly similar
distribution of BRAF/NRAS mutations versus primary melanomas, with a significantly less
consistent pattern in brain (80%) and skin metastases (75%). This suggests that independent
subclones are generated in some patients. p16CDKN2A mutations were identified in 7% and 14%
of primary melanomas and metastases, with a low consistency (31%) between secondary and
primary tumor samples.
Conclusion
In the era of targeted therapies, assessment of the spectrum and distribution of alterations in
molecular targets among patients with melanoma is needed. Our findings about the prevalence of
BRAF/NRAS/p16CDKN2A mutations in paired tumor lesions from patients with melanoma may be
useful in the management of this disease.
J Clin Oncol 30:2522-2529. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Melanoma is a complex disease that arises through
multiple etiologic pathways. Studies of the genetic
and molecular characteristics of melanomas are
valuable in the development of new treatment
strategies. Mutations in the p16 cyclin-dependent
kinase inhibitor 2A (p16CDKN2A) gene, located
on chromosome 9p21, are the most recognized
cause of inherited melanoma susceptibility,1,2
contributing to geographic variations in inci-
dence. In Italy, there is a gradient of melanoma
incidence— higher in northern regions and lower
in southern regions; such a gradient has been
analogously described for the p16CDKN2A muta-
tion prevalence.3,4
The MAPK-ERK pathway, which includes
the cascade of BRAF, NRAS, MEK1/2, and ERK1/2
gene products, also plays a major role in the develop-
ment and progression of melanoma.5,6 Mutations of
BRAF and NRAS genes have been identified with high
frequency in nevi and cutaneous melanomas, suggest-
ing that they represent early events in the development
of melanocytic tumors.7-9 Furthermore, melanomas
on skin that have not been chronically exposed to sun
usually carry either a mutated BRAF or a mutated
NRAS (somatic mutations in such genes are mutu-
ally exclusive).8,10-12
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Similar rates of BRAF mutations are present in primary and
metastatic melanomas, as well as in cultured malignant melanoma
cell lines, suggesting that BRAF mutations occur before tumor
dissemination and that their incidence remains constant during
tumor progression.6 However, prevalence of such mutations dur-
ing the disease progression phases and among different types of
metastasis remains inconclusive. The aim of this study was to
investigate the prevalence and distribution of pathogenetic muta-
tions in BRAF, NRAS, and p16CDKN2A genes among primary and
metastatic melanoma tissues.
PATIENTS AND METHODS
Patients
Eligible patients had a histologically proven diagnosis of advanced
melanoma (disease stages III and IV, according to American Joint Com-
mittee on Cancer [AJCC] guidelines)13 and had primary and metastatic
tumor tissue samples available for molecular analysis. Patients were en-
rolled consecutively between June 2008 and December 2010 from centers
in Italy. To avoid bias, patients were included regardless of age of onset,
family history of cancer, and disease characteristics. About one tenth of the
present cohort (12 patients) had been tested for BRAF/NRAS/p16CDKN2A
somatic mutations previously.4
Patients were informed about the study aims and limits, and they pro-
vided written consent for the molecular analysis of their tissue samples. The
study was reviewed and approved by the ethical review boards at both partic-
ipating centers.
Samples
Paired samples of primary melanomas and synchronous or asynchro-
nous metastases from the same patient were collected. Formalin-fixed,
paraffin-embedded (FFPE) tumor tissues were taken from pathologic ar-
chives. By using light microscopy, the neoplastic portion of each tissue section
was isolated to obtain tumor samples with at least 80% neoplastic cells (im-
proving the sensitivity of nucleotide sequencing, which may detect a mutation
when the mutant alleles are at least 15% to 20% of the analyzed DNA sample).
Histologic classification, including Breslow thickness and disease stage at di-
agnosis, was confirmed by medical records, pathology reports, and/or review
of pathologic material.
For reference, 29 melanoma cell lines cultured from primary and meta-
static excised tumors were obtained from Istituto Dermopatico
dell’Immacolata of Rome, the National Cancer Institute of Naples, and the
publicly available American Type Culture Collection (ATCC). The cell line
controls were obtained from primary tumors (n 6), lymph node metastases
(n 7), subcutaneous metastases (n 9), visceral metastases (n 2), and the
ATCC catalog (n5). These cell lines were established as primary cell cultures
from tumor samples from donor patients with documented diagnosis of
melanoma, after informed consent.
Tissue sections of brain metastases were obtained from 24 patients
surgically treated in other Italian clinical centers (after informed consent).
An additional cohort of patients with brain metastasis was included to
better assess the distribution of BRAF/NRAS mutations in such secondary
tumors.
Mutation Analysis
Genomic DNA was isolated from tumor tissues or melanoma cell
lines.14 For paraffin-embedded samples, paraffin was removed by xylene
treatment (Pisano et al14), and DNA was purified by using the QIAamp
DNA FFPE tissue kit (QIAGEN, Valencia, CA). Polymerase chain reaction
(PCR) was performed on 25 to 50 ng of isolated genomic DNA in a
9700 thermal cycler (Applied Biosystems, Foster City, CA); all PCR-
amplified products were directly sequenced by using an automated fluo-
rescent cycle sequencer (ABI PRISM 3130, Applied Biosystems), as
previously described.4
Sequencing analysis was conducted in duplicate—starting from two
different tumor sections and performing two different PCR-based ampli-
fications—and in both directions (forward and reverse) for all samples. For
discordant tumors, the sequence analysis was performed in triplicate—three
different tumor sections and three different PCR-based amplifications—to
avoid any chance of PCR artifacts. A nucleotide sequence was considered as
valid when the quality value was higher than 20 ( 1/100 error probability); in
this study, the quality value average was 35 (range, 30 to 45;  1/1,000 to
1/10,000 error probability).
Mutation screening was conducted to analyze the full coding sequences
and splice junctions of p16CDKN2A (exons 1, 2, and 3) and NRAS (exons 2
and 3) genes, and the entire sequence of the BRAF exons 11 and 15 (because
Paired tissues from same patients
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  Primary melanoma and other (n = 18)
    site metastasis
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Fig 1. Patients and tissues included in
the study.
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almost all pathogenetic mutations of BRAF have been detected at either the
kinase domain at exon 15 or the adenosine triphosphate–binding pocket at
exon 11).5,6 Primer sets and PCR assay protocols were as previously de-
scribed.4 To confirm that each CDKN2A gene variant detected by sequencing
was a real mutation or a polymorphism, 105 unrelated healthy individuals
(corresponding to 210 control chromosomes), originating from the same
geographic area and with no family history of cancer, were used as controls and
screened for candidate sequence variations.
Statistical Analysis
Univariate analysis of the presence of BRAF, NRAS, or p16CDKN2A
mutations versus the number and type of metastatic sites and primary mela-
noma locations was performed by using Pearson’s 2 test with the statistical
package SPSS version 7.5 for Windows (SPSS, Chicago, IL).
RESULTS
Patients and Samples
A total of 108 patients with advanced (AJCC stages III and IV13)
melanoma were enrolled, of whom nine were excluded (tissue DNA
degradation). Among the remaining 99 patients, paired samples of
primary melanomas (n 102; three patients had two primary tumors
each) and synchronous or asynchronous metastases (n 165) were
collected (Fig 1; Appendix Table A1, online only). Median age of the
99 enrolled patients was 52 years (range, 27 to 84 years); 58 (58%) were
women. Considering the 102 primary melanomas, trunk was the most
frequent location (trunk, 47 [46%]; limbs, 38 [37%]; head and neck,
17 [17%]); median Breslow thickness was 2.2 mm (range, 0.85 to 8.0
mm). In addition, 24 patients surgically treated in other Italian centers
provided tissue sections of brain metastases. Overall, a total of 291
tumor samples were screened for gene mutations from the sites shown
in Figure 1.
All mutations detected in this study have been reported previ-
ously in the Human Gene Mutation Database15 and in the Catalogue
of Somatic Mutations in Cancer (COSMIC).16
BRAF/NRAS Mutation Frequencies
BRAF or NRAS mutations were detected in 59 (58%) of 102
primary tumors: 44 (43%) BRAF and 15 (15%) NRAS. Among the 189
metastatic tissue samples, 119 (63%) carried mutations: 91 (48%)
BRAF and 28 (15%) NRAS. Similar frequencies of BRAF and NRAS
mutations were seen across metastatic sites (Table 1). In the control
melanoma cell lines, the equivalent rate of BRAF/NRAS mutations
was 21 (72%) of 29, including a BRAF mutation frequency of 17 (59%)
of 29 and NRAS mutation prevalence of four (14%) of 29 (Table 1). In
our series, no concomitant mutations of BRAF and NRAS genes
were detected.
All but one of the BRAF mutations across samples was of the
BRAF V600 subtype. Of these 135 mutations, 123 (91%) were BRAF
V600E, occurring in 42% of all patient samples (39% of primary
tumors and 44% of metastatic sites [range, 40% to 53%]). Likewise, 13
(45%) of the 29 control melanoma cell lines exhibited BRAF V600E
(76% of the 17 BRAF V600 mutations). Other V600 subtypes identi-
fied were V600K, V600D, and V600R (Table 1).
Among the 99 patients who had paired samples of primary
and secondary melanomas, 84 (85%) showed consistent mutation
patterns between primary tumors and metastatic lesions. In partic-
ular, the frequency of BRAF/NRAS mutations was highly consis-
tent between the primary tumor and metastases in the lymph nodes
and visceral sites. Of 84 patients with lymph node metastases, 78
(93%) had paired primary and secondary tumor samples that had
the same BRAF/NRAS mutations. Similarly, for visceral metasta-
ses, 24 (96%) of 25 patients showed similar BRAF/NRAS mutation
status between primary and secondary tumors (Table 2). However,
in patients with data available for brain and skin metastases, rates
of consistency in BRAF/NRAS mutations between primary and
secondary samples were significantly lower than for lymph and
visceral metastases: 16 (80%) of 20 (2 P  .0323) brain lesion
samples and 27 (75%) of 36 (2 P .001) skin secondary tumors
exhibited the same BRAF/NRAS mutation status as the paired
primary tumor (Table 2).
Among the 20 paired samples (15 [15%] of 99 patients) with
discrepancies in BRAF/NRAS mutation patterns between primary and
secondary tumors, 10 (50%) displayed a wild-type primary tumor and
a mutated metastasis (six in BRAF and four in NRAS), eight presented
with a mutated primary tumor and a wild-type metastasis (seven in
BRAF and one in NRAS), and two carried a change in mutation
Table 1. Somatic Mutations Detected in BRAF and NRAS Genes Among In
Vivo (primary and secondary tumor sites from patients with melanoma)
and In Vitro (melanoma cell lines) Samples
Sample
No. of
Samples
Frequency of Mutations and Subtypes
BRAF Mutation NRAS Mutation
BRAF or
NRAS
Mutation
Subtype No. % Subtype No. % No. %
Primary tumor 102 44 43 15 15 59 58
V600E 40 Q61R 10
V600K 3 Q61L 3
V600D 1 Q61K 2
All metastatic sites 189 91 48 28 15 119 63
V600E 83 Q61R 17
V600K 6 Q61L 8
V600D 1 Q61K 3
L597R 1
Lymph node
metastases 84 40 48 12 14 52 62
V600E 36 Q61R 9
V600K 3 Q61K 2
L597R 1 Q61L 1
Brain metastases 44 21 48 10 23 31 70
V600E 18 Q61R 4
V600K 2 Q61L 6
V600D 1
Skin metastases 36 19 53 3 8 22 61
Locoregional 22 11 50 2 9 13 59
Distant 14 8 57 1 7 9 64
V600E 19 Q61R 2
Q61L 1
Visceral metastases 25 11 44 3 12 14 56
Liver 20 9 45 2 10 11 55
Lung 5 2 40 1 20 3 60
V600E 10 Q61R 2
V600K 1 Q61K 1
Cell lines 29 17 59 4 14 21 72
V600E 13 Q61L 2
V600R 3 Q61K 1
V600D 1 Q61R 1
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pattern between the two tumor lesions (an NRAS mutation in primary
melanoma and a BRAF mutation in melanoma metastasis; Table 2).
Overall, nine of the 20 discrepant metastatic lesions occurred in only
four patients, whereas each of the remaining 11 patients carried a
single discrepant metastatic lesion (Table 3).
Concordance in BRAF/NRAS mutation status among metastatic
samples was then evaluated in the subset of 46 patients with paired
multiple metastases (one lymph node and at least one other site lesion;
Fig 1). Rates of consistency in BRAF/NRAS mutations between lymph
node and other site metastases were quite similar to those observed
between primary and secondary tissues: 21 (91%) of 23 visceral le-
sions, five (83%) of six brain metastases, and 25 (76%) of 33 skin
secondary tumors exhibited the same BRAF/NRAS mutation status as
the paired lymph node sample (Appendix Table A2, online only). The
BRAF/NRAS mutation status was not evaluated for association with
clinical outcome in our series.
p16CDKN2A Mutation Frequencies
Sixteen (16%) of the 99 patients had p16CDKN2A gene muta-
tions. Among available DNA samples, the rate of mutations was much
higher in melanoma metastases (21 [14%] of 151) versus primary
melanomas (five [7%] of 74). The rate of consistency between second-
ary and primary tumor samples was five (31%) of 16. The highest
prevalence of p16CDKN2A alterations was observed in our series of 29
melanoma control cell lines (62%; Table 4).
Table 5 shows the distribution of mutations in the
p16CDKN2A gene among the 16 patients identified as having this
mutation, showing that in most of these patients (11; 69%) muta-
tions existed only in metastatic sites, although the primary tumor
exhibited wild-type status.
Finally, no correlation was inferred between p16CDKN2A and
BRAF/NRAS mutations from either primary or secondary melanomas
(Appendix Table A3, online only). Regardless of p16CDKN2A muta-
tion status, approximately 60% of samples had BRAF or NRAS muta-
tions in both primary and metastatic sites.
DISCUSSION
Melanoma is a complex disease influenced by alterations in several
genes and metabolic pathways that continue to evolve through the
course of the disease. There is increasing evidence that melanoma
develops as a result of accumulated genetic abnormalities within me-
lanocytes.17 The MAPK-ERK pathway, which includes the cascade of
NRAS, BRAF, MEK1/2, and ERK1/2 proteins, is involved in the con-
trol of cell growth, proliferation, and migration. Mutations in this
pathway may play a major role in the development and progression of
melanoma.5 In addition, the p16CDKN2A protein acts as a suppressor
of cell proliferation, and dysfunction in this pathway is observed in
many types of cancer.18 In our study, we explored the relative fre-
quency of genetic factors known to play a significant role in melano-
cyte development and their distribution among different melanoma
tissues and disease progression sites.
As expected, a high prevalence of somatic mutations of BRAF
and NRAS genes was detected in primary and secondary melano-
mas. The frequency of BRAF/NRAS mutations in primary tumors
(43%/15%) was consistent with that reported in a meta-analysis in
which BRAF mutation was present in 41% of cutaneous melano-
mas (n 2,521 patients) and NRAS mutation in 18% (n 1,972
Table 2. Consistency Between BRAF/NRAS Mutation Status in Primary and Secondary Lesions in Patients With Melanoma and Mutation Patterns in Those in
Whom There Were Discrepancies
Tissue Type No. of Samples
Patients With Consistent Mutation Patterns
(secondary v primary melanoma samples)
Mutation Patterns Among Discrepant Paired Samples
No. %
BRAF NRAS
Primary Tumor Metastasis Primary Tumor Metastasis
Lymph node metastases 84 78 93 V600K wt wt wt
wt L597R wt wt
wt V600E wt wt
wt V600E wt wt
wt V600E wt wt
V600E wt wt wt
Visceral metastases 25 24 96 V600E wt wt wt
Brain metastases 20 16 80 V600E wt wt wt
wt wt wt Q61L
wt wt wt Q61L
wt wt wt Q61R
Skin metastases 36 27 75 wt wt wt Q61L
V600E wt wt wt
V600E wt wt wt
wt wt Q61R wt
wt V600E Q61R wt
wt V600E Q61R wt
wt V600E wt wt
wt V600E wt wt
V600E wt wt wt
Abbreviation: wt, wild-type.
BRAF/NRAS Mutation Frequencies in Melanoma
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patients).19 Confirming previous data,20 BRAF and NRAS muta-
tions were mutually exclusive in our tissue sample collection.
Overall, slightly higher rates of BRAF/NRAS mutation in meta-
static (63%) versus primary site samples (58%) were observed in
our series. A markedly higher rate of BRAF/NRAS mutations
(72%) was detected in the control melanoma cell lines, mostly due
to a higher BRAF mutation frequency (59% v 43% in primary tumors
and 48% in metastatic sites). Since cultured melanomas are thought to
represent cells with the most malignant phenotype, our observations
support previous findings21 in which selection of BRAF mutant alleles
may occur during tumor progression. In this regard, the demonstra-
tion of a sequential increase in mutation rates for both BRAF and
NRAS genes during melanoma progression—from in situ melanomas
to the radial and vertical growth phases of invasive melanomas22—
strongly suggests that BRAF/NRAS somatic mutations may not act as
founder events in melanomagenesis.
Twenty paired samples from 15 patients (15%) demonstrated
discrepancies in BRAF/NRAS mutation patterns between primary and
secondary tumors, the highest frequency of these discrepancies being
in patients with subcutaneous (25%; P  .001) or cerebral (20%;
P .0323) metastases. In half the discrepant cases, we found a wild-
type primary tumor and a mutated metastasis (60% BRAF and 40%
NRAS). Again, this may represent a further indication that mutations
in two such genes might be acquired and become prevalent during
disease dissemination in a fraction of patients with melanoma. How-
ever, the most intriguing data were represented by the observation of
wild-type metastases in cases with mutated primary tumors (nearly all
in BRAF) or, to a lesser extent, a different mutation pattern between
melanoma lesions (NRAS mutation in primary and BRAF mutation in
secondary tumors) in the remaining half of the discrepant cases. These
observations provide additional evidence that molecularly heteroge-
neous cell types may coexist in primary melanoma (presence of both
BRAF-wild-type and BRAF-mutant as well as differently mutated
tumor cells has indeed been described21-23). However, it is still unclear
Table 3. Patients With Discrepancies Between Primary Melanoma and
Paired Metastases in BRAF and NRAS Genes
Gene
and
Sample
No.
Primary
Melanoma
Metastasis Stage
I II III IV V
BRAF
1 wt L: L597R S: wt
2 wt L: wt S: wt S: V600E S: wt S: V600E
3 wt L: wt S: wt S: V600E S: wt
4 wt L: V600E S: V600E
5 wt L: V600E
6 wt L: V600E V: wt
7 wt B: wt
8 wt B: wt
9 wt B: wt
10 V600E L: V600E S: wt S: wt S: V600E S: V600E
11 V600E L: V600E V: wt
12 V600E L: wt
13 V600E S: wt
14 V600E B: wt
15 V600K L: wt V: V600K
NRAS
1 wt L: wt S: wt
2 Q61R L: Q61R S: Q61R S: wt S: wt S: wt
3 wt L: wt S: Q61L S: wt S: wt
4 wt L: wt S: wt
5 wt L: wt
6 wt L: wt V: wt
7 wt B: Q61L
8 wt B: Q61L
9 wt B: Q61R
10 wt L: wt S: wt S: wt S: wt S: wt
11 wt L: wt V: wt
12 wt L: wt
13 wt S: wt
14 wt B: wt
15 wt L: wt V: wt
NOTE. Discrepant results are shown in bold.
Abbreviations: B, brain; L, lymph node; S, skin; V, visceral; wt, wild-type.
Table 4. Number of Somatic p16CDKN2A Mutations Detected in Tissue
Samples From Patients With Melanoma and Melanoma Cell Lines
Sample No. of Samples
Frequency of
p16CDKN2A
Mutation
No. %
Primary tumors 74 5 7
Metastatic sites 151 21 14
Lymph nodes 64 9 14
Other sites 87 12 14
Melanoma cell lines 29 18 62
Gene mutations 8 28
Deletions/rearrangements 10 34
Table 5. Patients With Melanoma Who Are Positive for
p16CDKN2A Mutations
Patients
Primary
Melanoma
Lymph Node
Metastasis
Other Site
Metastasis
No. % No. % No. %
No. 16 15 10
Positive for
p16CDKN2A
mutation 5 31 12 80 9 90
p16CDKN2A subtype
wt IVS1  1GA wt
Arg24Pro Arg24Pro Arg24Pro
wt Arg80term Arg80term
Ala36Thr Ala36Thr —
Ala109Val Ala109Val —
Trp110term Trp110term Trp110term
wt Arg80term Arg80term
Arg24Pro Arg24Pro —
wt wt Arg24Pro
wt Trp110term Trp110term
wt Arg24Pro —
wt — Arg24Pro
wt Ala36Thr —
wt Val59Gly —
wt wt Arg24Pro
wt wt Trp110term
Abbreviation: wt, wild-type.
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what selective pressure induces the migration of a BRAF-wild-type
subclone instead of an expected more aggressive BRAF-mutant sub-
clone. One could speculate that cells with BRAF mutation might
undergo activation of the senescence pathways24 or downregulation of
the BRAF-NRAS-MEK-ERK cascade25; both events may determine
the proliferation arrest of BRAF/NRAS mutated cells. Alternatively,
one could hypothesize that the mutated metastasis may derive from
another unidentified primary melanoma (in a fraction of patients, no
known primary tumor is indeed found among those with meta-
static disease).
The BRAF V600E mutation was identified in 42% of tissue
samples and 45% of control melanoma cell lines, consistent with
the frequency observed in patients screened for inclusion in A
Study of Vemurafenib (RO5185426) in Comparison With Dacar-
bazine in Previously Untreated Patients With Metastatic Mela-
noma (BRIM 3), in which 47% of patients tested positive for the
BRAF V600 variants following BRAF mutation analysis with the
cobas-4800 BRAF-V600 Mutation Test.26 Although it remains
the most prevalent sequence variant reported in subsets of patients
with melanoma, the incidence of the BRAF V600E mutation varies
worldwide, from 23% in Chinese patients with melanoma27 to 45%
in Australian patients,28 in which it appears to be associated with
various clinical features such as an inverse association with cumu-
lative sun exposure and a lower rate of tumor proliferation. In our
series, other BRAF V600 mutation subtypes occurred in less than
10% of all samples (with V600K being the second most frequent
variant); lower than the rate of 26% recently described by Long et
al29 in Australian patients. All known mutations at position V600
of BRAF result in constitutive activation of BRAF kinase, causing
deregulated downstream signaling via MEK and ERK.30-32
A more striking difference in the mutation frequency between
primary melanoma, metastases, and cell lines was observed for
p16CDKN2A (7%, 14%, and 28%, respectively). Inactivation by
mutation of this gene seems to be selected during tumor progres-
sion; this is consistent with the finding that p16CDKN2A silencing
promotes uncontrolled cell proliferation, tumor growth, and in-
creased aggressiveness of tumor cells.33,34 Nevertheless, a func-
tional relationship between p16CDKN2A inactivation and BRAF
activation has been demonstrated. Oncogenic BRAF mutations
constitutively induce upregulation of p16CDKN2A in melanocytic
cells and, conversely, any genetic or epigenetic inactivation of
p16CDKN2A may contribute to malignant progression of BRAF
mutant cells.24,33 Consistent with these findings, BRAF/NRAS and
p16CDKN2A mutations were found to coexist (being detected at
similar rates of around 60%) in our series of primary tumors and
corresponding metastases.
Although p16CDKN2A remains a high penetrance melanoma
susceptibility gene, oncogenic BRAF now represents an identifiable
and proven target for cancer therapies.35,36 In melanoma, a phase III
study of oral vemurafenib, a potent inhibitor of BRAF V600 muta-
tions, demonstrated a relative reduction of 63% in the risk of death
and 74% in the risk of either death or disease progression compared
with dacarbazine chemotherapy in 675 patients carrying the BRAF
V600E mutation.26 Another inhibitor of mutated BRAF, GSK2118436
(GSK436), is under phase III evaluation in comparison with dacarba-
zine among BRAF-mutation–positive patients with stage III to IV
melanoma (NCT01227889). A phase I/II study indicated a tumor
response at 8 to 9 weeks in 60% of patients with metastatic melanoma
or other solid tumors.37 Despite evidence implicating NRAS in mela-
noma pathogenesis,17 this gene has not yet become an effective target
for melanoma treatment.
Together, these findings indicate that the future of melanoma
therapy is likely to focus on targeting multiple pathways. However,
the complexity of the molecular events underlying development
and progression of melanoma suggests that a better comprehen-
sion of both the spectrum and distribution of alterations in molec-
ular targets among patients with such a disease is crucial. In our
study, we contributed to provide additional clues about the prev-
alence of BRAF/NRAS/p16CDKN2A mutations in synchronous or
asynchronous paired tumor lesions from a large series of patients
with melanoma. The observation of a high consistency between
primary melanomas and lymph node or visceral metastases, in
contrast with a significantly lower consistency between primary
tumors and brain or skin metastases, may have implications in
clinical practice. Starting from these findings, the prognostic value
of such genetic alterations should be evaluated in a large cohort to
assess whether the different distribution of BRAF/NRAS/
p16CDKN2A mutations in tumor lesions may have an impact on
disease outcome among patients with melanoma.
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GLOSSARY TERMS
BRAF: BRAF is an isoform of RAF. Raf proteins (Raf-1, A-Raf,
B-Raf) are intermediate to Ras and MAPK in the cellular prolifer-
ative pathway. Raf proteins are typically activated by Ras via
phosphorylation, and activated Raf proteins in turn activate
MAPK via phosphorylation. However, Raf proteins may also be
independently activated by other kinases.
ERK (extracellular receptor kinase): A second messen-
ger kinase (an enzyme adding phosphate groups from ATP), ERK
belongs to the MAPK family and is responsible for transmitting
signals from the cellular surface to the nucleus by the activation
of transcription factors, including NF-B. It belongs to the prolif-
erative/mitogenic signal transduction pathway activated by ty-
rosine kinase receptors.
Formalin-fixed, paraffin-embedded: Formalin-fixed,
paraffin-embedded (FFPE) tissue is the standard for tissue preparation
in anatomic pathology. The processing of tissue historically has included
cutting into thin (5-mm) sections, then placing a cassette for fixation in
formalin in a tissue processor, followed by infusion of paraffin and em-
bedding on the block for subsequent sectioning for histologic evaluation
or immunohistochemistry.
MAPK(mitogen-activatedproteinkinase):MAPKs are a
family of enzymes that form an integrated network influencing cellular
functions such as differentiation, proliferation, and cell death. These
cytoplasmic proteins modulate the activities of other intracellular pro-
teins by adding phosphate groups to their serine/threonine amino acids.
NRAS:NRAS represents one of the three members of the Ras gene family
(HRAS and KRAS are the remaining family members). The Ras proteins are
typically small triphosphate-binding proteins, and are the common upstream
molecule of several signaling pathways that play a key role in signal transduc-
tion, which results in cellular proliferation and transformation.
p16CDKN2A:Also known as p16, it binds to cyclin-dependent kinase 4 and
6, thereby preventing their interaction with cyclin D. It thus behaves as a nega-
tive regulator of proliferation and arrests cells in the G0/G1 phase of the
cell cycle.
PCR(polymerasechainreaction):PCR is a method that allows loga-
rithmic amplification of short DNA sequences within a longer DNA molecule.
Polymorphism:Genetic polymorphisms are natural variations in the
genomic DNA sequence present in greater than 1% of the population, with SNP
(single nucleotide polymorphism) representing DNA variations in a single nu-
cleotide. SNPs are being widely used to better understand disease processes,
thereby paving the way for genetic-based diagnostics and therapeutics.
Sequencing:A laboratory process that determines the nucleotide sequence
of DNA (can involve the whole genome or whole exome or be targeted to as
little as one coding sequence). Unlike somatic mutation genotyping, sequencing
can detect previously unknown somatic mutations.
Somaticmutation:A change in the genotype of a cancer cell. This is distin-
guished from a germline mutation, which is a change in the genotype of all the
normal cells in a patient’s body. Germline mutations may be passed to off-
spring, but somatic mutations may not.
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